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Chlamydia pneumoniae has been associated
with atherosclerotic cardiovascular disease in
seroepidemiologic studies, by detection of the
organism in atherosclerotic plaque, and in
animal model studies (1-4). Two small clinical
trials to assess the effect of treatment with
antibiotics active against C. pneumoniae on
cardiovascular disease outcomes have indicated
a possible effect of azithromycin (5) or
roxithromycin (6) in the secondary prevention of
coronary heart disease. To evaluate whether
past use of antibiotics active against
C. pneumoniae is associated with decreased risk
for first myocardial infarction (MI), we
conducted a retrospective, population-based
case-control study of patients enrolled at Group
Health Cooperative of Puget Sound (GH),
Seattle, WA, USA.
The Study
Case-patients were GH enrollees, ages 30 to
79 years, in whom an incident fatal or nonfatal
MI was diagnosed during July 1986 through
December 1995. Controls were a stratified
random sample of GH enrollees frequency-
matched with the case-patients by age (within
decade), sex, calendar year, presence of treated
hypertension, and menopausal status (post
versus peri and premenopausal). The case-
patients and controls had been identified for two
previous cardiovascular studies, one of persons
with pharmacologically treated hypertension (7)
and one of postmenopausal women (8,9), by
using methods previously reported. Therefore,
men and women with treated hypertension and
women without hypertension were included as
both case-patients and controls, but men without
hypertension were not included in the study
population. Medical records were reviewed for
all study participants to confirm the diagnosis of
incident MI (case-patients) and obtain informa-
tion on other cardiovascular risk factors.
All study participants had an index date. For
the hospitalized case-patients, it was the date of
admission for the first MI; for out-of-hospital
case-patients who died, it was the date of death;
and for the controls, it was a computer-generated
random date within the calendar year for which
they had been sampled as controls. We excluded
persons who had been enrolled for fewer than 5
years or had fewer than four visits to a GH
provider before their index date.
The GH computerized pharmacy database,
which contains records of all prescriptions
dispensed at GH pharmacies, was used to assess
prescriptions for antibiotics. A survey conducted
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in conjunction with the previous study of
postmenopausal women determined that 95% of
study participants filled all their prescriptions at
a GH pharmacy (9). During the period of interest
to this study, newer macrolidelike antibiotics
such as azithromycin and clarithromycin were
not routinely available at GH; thus, we selected
erythromycin, tetracycline, and doxycycline,
antibiotics available for routine use during this
period, for evaluation because of their in vitro
activity against C. pneumoniae and their
indication for treatment of C. pneumoniae
respiratory infections. To determine duration of
use for each agent, we defined 1 day of use as
equivalent to 2 g erythromycin, 2 g tetracycline,
or 100 mg doxycycline. The total duration of
therapy with these drugs was calculated by
using the sum of the quantities dispensed during
the 5 years before the index date.
The Findings
We identified 1,796 eligible case-patients
with an incident fatal or nonfatal MI and 4,882
eligible controls during the study period (Table
1). At least one prescription for erythromycin,
tetracycline, or doxycycline was recorded for 775
(43%) of the case-patients and 2,061 (42%) of the
controls. In multivariate logistic regression
models controlling for the matching variables
(age, sex, hypertension status, menopausal
status, and index year) or the matching variables
and known cardiac risk factors (smoking,
diabetes, cardiovascular disease), risk for
incident MI was not associated with the
cumulative duration of prescribed treatment
with erythromycin, tetracycline, doxycycline, or
the three agents combined (Table 2). In addition,
risk for incident MI was not associated with
increasing cumulative duration of therapy
across these categories for any of the agents
individually or for the three agents combined.
Further, no association was detected when
assessment of the use of antibiotics was
restricted to 1 year before the index date (data
not shown).
There are several possible explanations for
these findings. Treatment with antibiotics active
against C. pneumoniae may not affect the risk for
heart disease, either because C. pneumoniae
does not play a causal role in the atherosclerotic
process or because its effect on that process
cannot be modified by antibiotics. Although two
published clinical trials have suggested a
protective effect of antibiotics on the secondary
prevention of coronary outcomes, these findings
are not conclusive. The study of azithromycin (5),
which enrolled 80 men with a history of MI who
had serologic evidence of C. pneumoniae, was not
a randomized controlled trial and so was subject
to bias. The results reported from the
roxithromycin study (6), which randomized
patients hospitalized for unstable angina or non-
Q wave infarctions to 1 month of treatment with
roxithromycin or placebo, were preliminary
findings from the first 31 days of the 6-month
follow-up. Even if the protective effect indicated
by the preliminary analysis persists in the final
analysis, further studies will be needed to
replicate and confirm those findings. Increasing
evidence supports a causal association of
C. pneumoniae and atherosclerotic disease;
however, additional data are needed to validate
this hypothesis.
    Alternatively, treatment with antichlamydial
antibiotics may be associated with a protective
effect, but this effect may vary depending on the
specific agent; the dose, duration, or timing of
treatment; or the patients clinical status.
Azithromycin and roxithromycin (both highly
active against C. pneumoniae in vitro) achieve
much higher intracellular levels, and in
particular much higher levels in macrophages,
than do erythromycin, doxycycline, or tetracy-
cline; they also have longer half-lives than those
agents (10,11). The beneficial effect of
roxithromycin in the published clinical trial may
have been due to a nonspecific antiinflammatory
effect (12,13) rather than to a direct antimicro-
bial effect. A true cardiovascular protective effect
associated with azithromycin or roxithromycin
treatment may not, therefore, be seen after
treatment with erythromycin, tetracycline, or
Table 1. Characteristics of case-patients with myocar-
dial infarction and controls
Case-patients Controls
Variable      n=1,796 n=4,882
Mean age (yr) 67.0 66.7
Male 38% 41%
Mean duration of 16.8 17.4
  enrollment in GHa (yr)
Angina 26% 10%
Hypertension 75% 70%
Diabetes mellitus 27% 12%
Current smoker 28% 15%
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Table 2. Cumulative duration of prescribed treatment with erythromycin, tetracycline, doxycycline, and the three
agents combined, and the risk for incident myocardial infarction
Cumulative
duration Case-patients Controls ORb ORc
Drug (day)a (n=1,796) (%) (n=4,882) (%) (95% CI) (95% CI)
Erythromycin   0   1,266 (70)   3,493 (72) 1.0 reference 1.0 reference
  1-14    401 (22) 1,124 (23) 0.99 (0.87-1.13) 0.91 (0.79-1.05)
15-28      92   (5)    182   (4) 1.41 (1.08-1.82) 1.18 (0.89-1.54)
29+      37   (2)      83   (2) 1.23 (0.83-1.83) 1.05 (0.69-1.59)
Tetracycline   0 1,507 (84) 4,149 (85) 1.0   reference 1.0   reference
  1-14    223 (12)    564 (12) 1.11 (0.94-1.31) 1.02 (0.86-1.22)
15-28      39   (2)      88   (2) 1.24 (0.84-1.81) 1.04 (0.69-1.55)
29+      27   (2)      81   (2) 0.95 (0.61-1.47) 0.98 (0.62-1.54)
Doxycycline   0 1,597 (89) 4,365 (89) 1.0 reference 1.0 reference
  1-14      37   (2)      86   (2) 1.18 (0.79-1.74) 1.06 (0.71-1.59)
15-28      85   (5)     244  (5) 0.94 (0.73-1.22) 0.90 (0.69-1.18)
29+      77   (4)     187  (4) 1.10 (0.84-1.45) 1.17 (0.88-1.56)
Erythromycin,   0 1,021 (57) 2,821 (58) 1.0 reference 1.0 reference
  tetracycline,   1-14    422 (24) 1,178 (24) 0.99 (0.87-1.14) 0.93 (0.81-1.07)
  or doxycycline 15-28    185 (10)     454  (9) 1.13 (0.94-1.35) 0.99 (0.81-1.20)
29+    168   (9)     421  (9) 1.11 (0.91-1.34) 1.03 (0.84-1.26)
aFor duration of each agent, 1 day is equivalent to 2 g erythromycin, 2 g tetracycline, or 100 mg doxycycline.
bAdjusted for sex, age, hypertension status, menopausal status, and index year.
cAdjusted for sex, age, hypertension status, menopausal status, index year, smoking status, diabetes, and cardiovascular
disease.
OR = odds ratio; CI = confidence interval.
doxycycline because of differences in pharmaco-
dynamics or in the mechanisms of action of those
agents. Additionally, in our study population,
the cumulative duration of treatment with the
antibiotics assessed was relatively limited; only
9% of all participants had been prescribed more
than a total of 28 days of treatment with the
three antibiotics combined during the 5-year
study period. Thus, the exposure to antibiotics in
routine clinical care may be insufficient to
reduce risk. A protective effect of antibiotic
treatment may also be limited to the secondary,
but not the primary, prevention setting; to
patients in the high-risk period after an acute
event; or to subsets of patients defined by factors
that we could not evaluate, such as seropositivity
to C. pneumoniae. Further, if the organism plays
a role during the initiation or early progression
of atherosclerotic lesions, but not in later stages,
treatment of older adults may not be effective.
Lastly, while it is possible that our study may
have failed to detect a true beneficial effect of
past antibiotic treatment, our sample size was
relatively large. Assuming a prevalence of
exposure among the control group of 42%, this
sample size had 90% power (at a 95% confidence
level) to detect a 20% reduction in risk associated
with antibiotic use.
In summary, even though the results of two
small clinical trials have suggested that newer
macrolidelike antibiotics active against
C. pneumoniae may provide effective secondary
prevention of coronary artery disease, their
effectiveness in the primary prevention setting
has not been evaluated prospectively. Our
results suggest that treatment with erythromy-
cin, tetracycline, and doxycycline in doses
commonly prescribed in routine clinical practice
is not associated with a reduction in the risk for
incident MI among our study population.
Further clinical trials of the newer agents for
secondary prevention and further observational
studies of these agents for the primary
prevention of heart disease are indicated.
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